

NCT02519777 comparison:

Summary:
CHIA has 40 criteria while your personal folder has 40 criteria
Total found criteria: 39/40
Total not Found: 1/40
Total Extra: 7
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ a licensed rapid HIV test or HIV enzyme or         │ a licensed rapid HIV test or HIV enzyme or         │
│ chemiluminescence immunoassay (E/CIA) test kit at  │ chemiluminescence immunoassay (E/CIA) test kit at  │
│ any time prior to study entry and confirmed by a   │ any time prior to study entry and confirmed by a   │
│ licensed Western blot or a second antibody test by │ licensed Western blot or a second antibody test by │
│ a method other than the initial rapid HIV and/or   │ a method other than the initial rapid HIV and/or   │
│ E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA     │ E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA     │
│ viral load. NOTE: The term "licensed" refers to a  │ viral load. NOTE: The term "licensed" refers to a  │
│ United States Food and Drug Administration         │ United States Food and Drug Administration         │
│ (FDA)-approved kit, which is required for all IND  │ (FDA)-approved kit, which is required for all IND  │
│ studies, or for sites located in countries other   │ studies, or for sites located in countries other   │
│ than the United States, a kit that has been        │ than the United States, a kit that has been        │
│ certified or licensed by an oversight body within  │ certified or licensed by an oversight body within  │
│ that country and validated internally. Non-US      │ that country and validated internally. Non-US      │
│ sites are encouraged to use US FDA-approved        │ sites are encouraged to use US FDA-approved        │
│ methods for IND studies. WHO (World Health         │ methods for IND studies. WHO (World Health         │
│ Organization) and CDC (Centers for Disease Control │ Organization) and CDC (Centers for Disease Control │
│ and Prevention) guidelines mandate that            │ and Prevention) guidelines mandate that            │
│ confirmation of the initial test result must use a │ confirmation of the initial test result must use a │
│ test that is different from the one used for the   │ test that is different from the one used for the   │
│ initial assessment. A reactive initial rapid test  │ initial assessment. A reactive initial rapid test  │
│ should be confirmed by either another type of      │ should be confirmed by either another type of      │
│ rapid assay or an E/CIA that is based on a         │ rapid assay or an E/CIA that is based on a         │
│ different antigen preparation and/or different     │ different antigen preparation and/or different     │
│ test principle (eg, indirect versus competitive),  │ test principle (eg, indirect versus competitive),  │
│ or a Western blot or a plasma HIV-1 RNA. OR        │ or a Western blot or a plasma HIV-1 RNA. OR        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documentation of HIV diagnosis in the medical      │ Documentation of HIV diagnosis in the medical      │
│ record by a healthcare provider                    │ record by a healthcare provider                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Tenofovir disoproxil fumarate (TDF) to tenofovir   │ Tenofovir disoproxil fumarate (TDF) to tenofovir   │
│ alafenamide fumarate (TAF)/TAF-containing fixed-   │ alafenamide fumarate (TAF)/TAF-containing fixed-   │
│ dose combination regimens                          │ dose combination regimens                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ritonavir (RTV) to cobicistat (COBI)/COBI-         │ Ritonavir (RTV) to cobicistat (COBI)/COBI-         │
│ containing fixed-dose combination regimens         │ containing fixed-dose combination regimens         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ TDF to TAF/TAF-containing fixed-dose combination   │ TDF to TAF/TAF-containing fixed-dose combination   │
│ regimens                                           │ regimens                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ RTV to COBI/COBI-containing fixed-dose combination │ RTV to COBI/COBI-containing fixed-dose combination │
│ regimens                                           │ regimens                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HIV-1 plasma RNA less than 50 copies/mL obtained   │ HIV-1 plasma RNA less than 50 copies/mL obtained   │
│ within 90 days prior to study entry by any FDA-    │ within 90 days prior to study entry by any FDA-    │
│ approved assay at any United States laboratory     │ approved assay at any United States laboratory     │
│ that has a Clinical Laboratory Improvement         │ that has a Clinical Laboratory Improvement         │
│ Amendments (CLIA) certification or its equivalent, │ Amendments (CLIA) certification or its equivalent, │
│ or at any network-approved non-US laboratory that  │ or at any network-approved non-US laboratory that  │
│ operates in accordance with Good Clinical          │ operates in accordance with Good Clinical          │
│ Laboratory Practices (GCLP) and participates in    │ Laboratory Practices (GCLP) and participates in    │
│ appropriate external quality assurance programs    │ appropriate external quality assurance programs    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No more than one HIV-1 plasma RNA greater than or  │ No more than one HIV-1 plasma RNA greater than or  │
│ equal to 50 and less than 200 copies/mL (only one  │ equal to 50 and less than 200 copies/mL (only one  │
│ "blip") in the past 6 months with a subsequent     │ "blip") in the past 6 months with a subsequent     │
│ HIV-1 plasma RNA less than 50 copies/mL. NOTE:     │ HIV-1 plasma RNA less than 50 copies/mL. NOTE:     │
│ There should be no plasma HIV-1 RNA greater than   │ There should be no plasma HIV-1 RNA greater than   │
│ 200 copies/mL within the 6 months prior to study   │ 200 copies/mL within the 6 months prior to study   │
│ entry                                              │ entry                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HAND diagnosis (ANI, MND, or HAD) within 60 days   │ HAND diagnosis (ANI, MND, or HAD) within 60 days   │
│ prior to study entry. HAND is defined as at least  │ prior to study entry. HAND is defined as at least  │
│ mild impairment on neurocognitive testing (more    │ mild impairment on neurocognitive testing (more    │
│ than one standard deviation below appropriate      │ than one standard deviation below appropriate      │
│ normative data in two domains of functioning) and  │ normative data in two domains of functioning) and  │
│ no severely confounding factors                    │ no severely confounding factors                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute neutrophil count (ANC) greater than or    │ Absolute neutrophil count (ANC) greater than or    │
│ equal to 500/mm^3                                  │ equal to 500/mm\^3                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin greater than or equal to 7.5 g/dL       │ Hemoglobin greater than or equal to 7.5 g/dL       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count greater than or equal to            │ Platelet count greater than or equal to            │
│ 40,000/mm^3                                        │ 40,000/mm\^3                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Creatinine less than or equal to 2.0 x upper limit │ Creatinine less than or equal to 2.0 x upper limit │
│ of normal (ULN)                                    │ of normal (ULN)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Aspartate transaminase (AST) less than or equal to │ Aspartate transaminase (AST) less than or equal to │
│ 5 x ULN                                            │ 5 x ULN                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alanine transaminase (ALT) less than 3 x ULN       │ Alanine transaminase (ALT) less than 3 x ULN       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alkaline phosphatase less than or equal to 5 x ULN │ Alkaline phosphatase less than or equal to 5 x ULN │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total bilirubin less than 1.5 x ULN. NOTE: If the  │ Total bilirubin less than 1.5 x ULN. NOTE: If the  │
│ potential participant is taking an indinavir       │ potential participant is taking an indinavir       │
│ (IDV)- or atazanavir (ATV)-containing regimen at   │ (IDV)- or atazanavir (ATV)-containing regimen at   │
│ the time of screening, total bilirubin less than   │ the time of screening, total bilirubin less than   │
│ or equal to 5 x ULN is acceptable                  │ or equal to 5 x ULN is acceptable                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Creatinine clearance (CrCl) greater than or equal  │ Creatinine clearance (CrCl) greater than or equal  │
│ to 60 mL/min, either measured or estimated by      │ to 60 mL/min, either measured or estimated by      │
│ Cockcroft-Gault equation. NOTE: A calculator for   │ Cockcroft-Gault equation. NOTE: A calculator for   │
│ estimating the CrCl can be found at                │ estimating the CrCl can be found at                │
│ www.fstrf.org/ACTG/ccc.html                        │ www.fstrf.org/ACTG/ccc.html                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of reproductive potential (women who have  │ Females of reproductive potential (women who have  │
│ not been post-menopausal for at least 24           │ not been post-menopausal for at least 24           │
│ consecutive months, ie, who have had menses within │ consecutive months, ie, who have had menses within │
│ the preceding 24 months, or women who have not     │ the preceding 24 months, or women who have not     │
│ undergone surgical sterilization, hysterectomy or  │ undergone surgical sterilization, hysterectomy or  │
│ bilateral salpingectomy or bilateral oophorectomy  │ bilateral salpingectomy or bilateral oophorectomy  │
│ or tubal ligation) must have a negative serum or   │ or tubal ligation) must have a negative serum or   │
│ urine pregnancy test by any US clinic or           │ urine pregnancy test by any US clinic or           │
│ laboratory that has a CLIA certification or its    │ laboratory that has a CLIA certification or its    │
│ equivalent, or is using a point of care (POC) /    │ equivalent, or is using a point of care (POC) /    │
│ CLIA-waived test, or at any network-approved non-  │ CLIA-waived test, or at any network-approved non-  │
│ US laboratory or clinic that operates in           │ US laboratory or clinic that operates in           │
│ accordance with GCLP and participates in           │ accordance with GCLP and participates in           │
│ appropriate external quality assurance programs    │ appropriate external quality assurance programs    │
│ within 48 hours prior to study entry               │ within 48 hours prior to study entry               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of reproductive potential must agree not   │ Females of reproductive potential must agree not   │
│ to participate in the conception process (ie,      │ to participate in the conception process (ie,      │
│ active attempt to become pregnant, in vitro        │ active attempt to become pregnant, in vitro        │
│ fertilization), and if participating in sexual     │ fertilization), and if participating in sexual     │
│ activity that could lead to pregnancy, must use at │ activity that could lead to pregnancy, must use at │
│ least one reliable form of contraception. Female   │ least one reliable form of contraception. Female   │
│ participants must use contraceptives while         │ participants must use contraceptives while         │
│ receiving study treatment and for 6 weeks after    │ receiving study treatment and for 6 weeks after    │
│ stopping study treatment. More information on this │ stopping study treatment. More information on this │
│ criterion is available in the protocol             │ criterion is available in the protocol             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability and willingness of participant or a        │ Ability and willingness of participant or a        │
│ legally authorized representative (see protocol    │ legally authorized representative (see protocol    │
│ for more information) to provide informed consent  │ for more information) to provide informed consent  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability and willingness to take oral study         │ Ability and willingness to take oral study         │
│ medications                                        │ medications                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major depressive disorder with psychotic features  │ Major depressive disorder with psychotic features  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Traumatic Brain Injury (TBI) with a clear impact   │ Traumatic Brain Injury (TBI) with a clear impact   │
│ on activities of daily living                      │ on activities of daily living                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Developmental delay, intellectual deficit, and/or  │ Developmental delay, intellectual deficit, and/or  │
│ severe educational disability resulting in some    │ severe educational disability resulting in some    │
│ dependence for activities of daily living          │ dependence for activities of daily living          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing substance use disorder with significant    │ Ongoing substance use disorder with significant    │
│ impact on activities of daily living. Difficult or │ impact on activities of daily living. Difficult or │
│ impossible to determine whether cognitive or       │ impossible to determine whether cognitive or       │
│ functional decline is due to substance use or HIV, │ functional decline is due to substance use or HIV, │
│ or both                                            │ or both                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of intoxication or withdrawal during the  │ Evidence of intoxication or withdrawal during the  │
│ screening evaluation                               │ screening evaluation                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Central nervous system (CNS) infections or         │ Central nervous system (CNS) infections or         │
│ opportunistic conditions: brain abscess            │ opportunistic conditions: brain abscess            │
│ (bacterial, mycobacterial, fungal or Toxoplasma),  │ (bacterial, mycobacterial, fungal or Toxoplasma),  │
│ meningitis with persistent neurologic impairment,  │ meningitis with persistent neurologic impairment,  │
│ primary CNS lymphoma, progressive multifocal       │ primary CNS lymphoma, progressive multifocal       │
│ leukoencephalopathy (PML), or another structural   │ leukoencephalopathy (PML), or another structural   │
│ brain lesion with neurological sequelae            │ brain lesion with neurological sequelae            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other CNS conditions: non-opportunistic primary or │ Other CNS conditions: non-opportunistic primary or │
│ metastatic brain tumors, uncontrolled seizure      │ metastatic brain tumors, uncontrolled seizure      │
│ disorder, progressive multiple sclerosis, stroke   │ disorder, progressive multiple sclerosis, stroke   │
│ with neurological sequelae, or dementia due to     │ with neurological sequelae, or dementia due to     │
│ causes other than HIV (eg, Alzheimer's disease)    │ causes other than HIV (eg, Alzheimer's disease)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Constitutional illness (eg, persistent unexplained │ Constitutional illness (eg, persistent unexplained │
│ fever, diarrhea, significant weight loss,          │ fever, diarrhea, significant weight loss,          │
│ disabling weakness) within 30 days of screening    │ disabling weakness) within 30 days of screening    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known untreated B12 deficiency or malnutrition     │ Known untreated B12 deficiency or malnutrition     │
│ (body mass index [BMI] less than 18) at screening  │ (body mass index \[BMI\] less than 18) at          │
│                                                    │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of current hepatitis C virus infection    │ Evidence of current hepatitis C virus infection    │
│ (HCV) (ie, HCV antibody [Ab] positive within 90    │ (HCV) (ie, HCV antibody \[Ab\] positive within 90  │
│ days prior to study entry unless also shown to be  │ days prior to study entry unless also shown to be  │
│ plasma HCV RNA negative within the same time       │ plasma HCV RNA negative within the same time       │
│ period)                                            │ period)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unstable and advanced liver disease (as defined by │ Unstable and advanced liver disease (as defined by │
│ the presence of at least one of the following:     │ the presence of at least one of the following:     │
│ ascites, encephalopathy, coagulopathy,             │ ascites, encephalopathy, coagulopathy,             │
│ hypoalbuminemia, esophageal or gastric varices, or │ hypoalbuminemia, esophageal or gastric varices, or │
│ persistent jaundice)                               │ persistent jaundice)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior or current use of any CCR5 antagonist (such  │ Prior or current use of any CCR5 antagonist (such  │
│ as MVC and cenicriviroc [CVC]) and integrase       │ as MVC and cenicriviroc \[CVC\]) and integrase     │
│ inhibitor (such as RAL, DTG, and elvitegravir      │ inhibitor (such as RAL, DTG, and elvitegravir      │
│ [EVG])                                             │ \[EVG\])                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of any medication, including           │ Current use of any medication, including           │
│ antiretrovirals, prohibited in the study (refer to │ antiretrovirals, prohibited in the study (refer to │
│ the A5324 protocol-specific web page [PSWP] for    │ the A5324 protocol-specific web page \[PSWP\] for  │
│ the prohibited medications)                        │ the prohibited medications)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Breastfeeding                                      │ Breastfeeding                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of an AIDS-defining opportunistic         │ Presence of an AIDS-defining opportunistic         │
│ infection within 6 months prior to entry. Note:    │ infection within 6 months prior to entry. Note:    │
│ Refer to the A5324 Manual of Operations (MOPS) for │ Refer to the A5324 Manual of Operations (MOPS) for │
│ the list of AIDS-defining opportunistic infections │ the list of AIDS-defining opportunistic infections │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active syphilis or treatment for syphilis within   │ Active syphilis or treatment for syphilis within   │
│ 90 days prior to study entry. NOTE: Active         │ 90 days prior to study entry. NOTE: Active         │
│ syphilis is defined as four-fold increase in serum │ syphilis is defined as four-fold increase in serum │
│ rapid plasma reagin (RPR) or venereal disease      │ rapid plasma reagin (RPR) or venereal disease      │
│ research laboratory (VDRL) tests in an individual  │ research laboratory (VDRL) tests in an individual  │
│ with past syphilis, or newly reactive serum RPR or │ with past syphilis, or newly reactive serum RPR or │
│ VDRL with a reactive confirmatory test (enzyme     │ VDRL with a reactive confirmatory test (enzyme     │
│ immunoassays [EIA] or chemiluminescent assay       │ immunoassays \[EIA\] or chemiluminescent assay     │
│ [CIA], T. pallidum particle agglutination [TP-PA], │ \[CIA\], T. pallidum particle agglutination \[TP-  │
│ or fluorescent treponemal antibody absorbed [FTA-  │ PA\], or fluorescent treponemal antibody absorbed  │
│ ABS])                                              │ \[FTA-ABS\])                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known allergy/sensitivity or any hypersensitivity  │ Known allergy/sensitivity or any hypersensitivity  │
│ to components of study drugs or their formulation  │ to components of study drugs or their formulation  │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                           │
╞═══════════════════════════════════════════════════════════════════════════════════════════════╡
│ Men and women 18 years of age and older who are able to complete the neuropsychological tests │
╘═══════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ HIV-1 infection, documented by                                                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ No plans to change ART while on study. Note: The following planned ART changes are allowed           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Screening laboratory values obtained within 60 days prior to study entry by any US laboratory that   │
│ has a CLIA certification or its equivalent, or at any network-approved non-US laboratory that        │
│ operates in accordance with GCLP and participates in appropriate external quality assurance programs │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Current or past medical condition(s) that in the opinion of the investigator prevents attribution of │
│ the cause of cognitive impairment to HIV. For example                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Ability and willingness of participant to complete the neuropsychological tests                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ On current ART for at least 6 months prior to study entry with no interruption in treatment of       │
│ greater than or equal to 7 consecutive days. Note: The following ART changes are allowed             │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛